Leukemia Breakthrough: Combining Breast Cancer Drug with Standard Treatment Shows Promise
A research team at Oregon Health & Science University (OHSU) has identified a promising drug combination that could help patients with acute myeloid leukemia (AML) overcome resistance to frontline therapies. This discovery offers a beacon of hope in a challenging landscape where treatment resistance remains a significant hurdle.
The Power of Synergy: Venetoclax and Palbociclib
Published in Cell Reports Medicine, the study analyzed over 300 patient samples with AML. Researchers found that combining venetoclax, a standard AML treatment, with palbociclib, a cell cycle inhibitor currently approved for breast cancer, demonstrated significantly more potent and durable anti-leukemic activity than venetoclax alone. Crucially, these findings were validated in both human tissue samples and mouse models using human leukemia cells.
“Of the 25 drug combinations we analyzed, venetoclax plus palbociclib was the most effective,” explains Dr. Melissa Stewart, lead author of the study and Assistant Professor of Research at OHSU. “This motivated us to investigate its efficacy in depth and understand why it appears to overcome observed resistance with current therapy.”
Addressing the Challenge of Resistance
Since its FDA approval in 2019, the combination of venetoclax and azacitidine has rapidly become a standard treatment for many AML patients. However, resistance remains a near-universal problem. As Dr. Jeffrey Tyner, the study’s corresponding author and Professor of Cellular, Developmental and Cancer Biology at OHSU School of Medicine, points out, “Unfortunately, almost all patients will develop resistance to treatment over time.”
Despite improvements in initial response rates and quality of life, the five-year survival rate for AML remains between 25% and 40%. This underscores the urgent need for new therapeutic strategies.
How the Combination Works: Blocking Adaptation
The research revealed that AML cells exposed solely to venetoclax attempt to adapt by increasing protein production – a mechanism that helps them survive. Palbociclib, however, effectively blocks this adaptation by regulating the machinery responsible for protein production within the cell. This dual-action approach appears to be key to overcoming resistance.
“Patient samples that responded strongly to the combination showed a clear decrease in the regulation of genes involved in protein synthesis. This was a key clue,” Stewart emphasizes.
Further analysis using a whole-genome CRISPR screen showed that while venetoclax alone becomes more effective when genes involved in protein production are lost, the combined therapy doesn’t rely on this same vulnerability. This suggests the two drugs work synergistically to shut down multiple survival pathways.
Impressive Results in Mouse Models
The research team tested the combination in mouse models implanted with human AML cells carrying mutations known to cause venetoclax resistance. The results were striking. “In this model, venetoclax alone did not prolong survival at all, as expected given the genetics. But with the combination, most of the mice lived between 11 and 12 months. In fact, one mouse was still alive at the end of the study,” Stewart notes.
Future Directions: Expanding the Therapeutic Arsenal
The OHSU team is already evaluating other drugs similar to palbociclib – many of which are also approved for breast cancer – to broaden potential options for future clinical trials. They are optimistic that this combination will move into clinical trials soon.
“We haven’t tested this in patients yet, but based on everything we’ve seen, our prediction is that this combination will mitigate most of the known mechanisms of resistance to the current standard therapy,” Tyner concludes. “Making that a clinical reality will require work, but that’s precisely why we do what we do.”
The Broader Implications: Precision Oncology and Drug Repurposing
This research highlights the growing trend of precision oncology, where treatments are tailored to the specific genetic characteristics of a patient’s cancer. It also exemplifies the power of drug repurposing – finding new uses for existing medications. This approach can significantly accelerate the development of new therapies, as the drugs have already undergone safety testing.
Did you know? AML is a particularly aggressive form of cancer, accounting for approximately 30% of all new leukemia cases in adults.
FAQ: Understanding the Potential of this New Combination
- What is AML? Acute myeloid leukemia is a cancer of the blood and bone marrow characterized by the rapid growth of abnormal white blood cells.
- How does venetoclax work? Venetoclax targets a protein called BCL-2, which helps leukemia cells survive.
- What is palbociclib and how does it help? Palbociclib is a CDK4/6 inhibitor that blocks cell cycle progression, preventing leukemia cells from dividing and multiplying.
- When will this combination be available to patients? The combination is currently in pre-clinical stages and needs to undergo clinical trials before it can be approved for patient use.
- Is this combination effective for all types of AML? Further research is needed to determine the effectiveness of the combination across different subtypes of AML.
Pro Tip: Staying informed about the latest advancements in cancer research is crucial for both patients and their families. Reliable sources include the American Cancer Society and the Leukemia & Lymphoma Society.
Have questions about AML or this new research? Share your thoughts in the comments below!
Explore more articles on cancer research and treatment: [Link to related article 1], [Link to related article 2]
Subscribe to our newsletter for the latest updates on medical breakthroughs and health news.
Worth a look